Comparison of the effectiveness and safety of two aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: a subgroup analysis of ADAPTABLE.

[1]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[2]  James R. Campbell,et al.  Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. , 2021, The New England journal of medicine.

[3]  D. Fliser,et al.  Cardiovascular Disease in Chronic Kidney Disease , 2021, Circulation.

[4]  Mahboob Rahman,et al.  Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis , 2020, Journal of clinical hypertension.

[5]  C. Reid,et al.  Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggest aspirin did not improve outcomes in older adults with chronic kidney disease. , 2020, Kidney international.

[6]  Catherine P. Benziger,et al.  Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. , 2020, JAMA cardiology.

[7]  A. Davenport,et al.  Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. , 2020, Kidney international.

[8]  L. Newby,et al.  Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[9]  A. Algra,et al.  Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study , 2018, Journal of thrombosis and haemostasis : JTH.

[10]  Adrian F. Hernandez,et al.  The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease , 2016, Current Cardiology Reports.

[11]  A. Garg,et al.  The Risk of Major Hemorrhage with CKD. , 2016, Journal of the American Society of Nephrology : JASN.

[12]  Chi Pang Wen,et al.  Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention , 2013, The Lancet.

[13]  A. Levin,et al.  Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[14]  T. Morimoto,et al.  Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate , 2011, Diabetes Care.

[15]  A. Zanchetti,et al.  Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. , 2010, Journal of the American College of Cardiology.

[16]  D. Charytan,et al.  The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. , 2006, Kidney international.

[17]  A. Garg,et al.  Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.

[18]  M. Landray,et al.  First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  V. Hasselblad,et al.  Seeking the optimal aspirin dose in acute coronary syndromes. , 2002, The American journal of cardiology.

[20]  S. Borzak,et al.  Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. , 2002, American heart journal.

[21]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[22]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[23]  N. Desai,et al.  Aspirin use in chronic kidney disease: Is cardiovascular risk reduction worth the risk? , 2021 .

[24]  G. Nadkarni,et al.  Representation of Patients With Kidney Disease in Trials of Cardiovascular Interventions: An Updated Systematic Review. , 2016, JAMA internal medicine.

[25]  E. Romagnoli,et al.  Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. , 2010, Preventive cardiology.

[26]  R. Becker,et al.  Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. , 2008, The American journal of medicine.

[27]  A. Day,et al.  Major bleeding in hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.